Massacesi Cristian, Galeazzi Giordano
Department of Oncology and Radiotherapy, Ospedali Riuniti Ancona, Ancona Istituto Oncologico Marche (IOM) for Palliative Care, Ancona, Italy.
Palliat Med. 2006 Oct;20(7):715-6. doi: 10.1191/0269216306070751.
Daily or continuous infusion octreotide is effective in relieving the gastrointestinal symptoms associated with inoperable malignant bowel obstruction (MBO). The sustained release (LAR) formulation of octreotide provides sustained exposure of the drug. This preliminary study aimed to investigate the efficacy of octreotide LAR (20 mg) for reducing gastrointestinal symptoms or nasogastric tube (NGT) secretions in patients with MBO. In patients with NGT (n = 8), octreotide LAR reduced NGT secretions from day one onwards, and NGT was removed in one patient. In patients without NGT (n = 4), octreotide LAR reduced episodes of vomiting and the severity of nausea, and this reduction was maintained throughout the study. Tolerability was good. In conclusion, the more convenient dosing schedule and potential activity of octreotide LAR may have a role in controlling MBO symptoms, and, therefore, it deserves further studies.
每日或持续输注奥曲肽可有效缓解与无法手术的恶性肠梗阻（MBO）相关的胃肠道症状。奥曲肽的缓释（LAR）制剂可使药物持续暴露。这项初步研究旨在调查奥曲肽LAR（20毫克）对减轻MBO患者胃肠道症状或鼻胃管（NGT）分泌的疗效。在有NGT的患者（n = 8）中，奥曲肽LAR从第一天起就减少了NGT分泌，一名患者的NGT被拔除。在没有NGT的患者（n = 4）中，奥曲肽LAR减少了呕吐发作次数和恶心严重程度，且这种减少在整个研究过程中持续存在。耐受性良好。总之，奥曲肽LAR更方便的给药方案和潜在活性可能在控制MBO症状方面发挥作用，因此值得进一步研究。
